Immunotherapy reduces cardiovascular risk in rheumatoid arthritis
Researchers found that an extra-low dose combination of two anticytokines reduced rheumatoid arthritis disease activity and cardiovascular events. The study showed a lower incidence of cardiovascular events in patients treated with the combination, suggesting decreased cardiovascular risk.